Diabetic Retinopathy: A Position Statement by the American Diabetes Association.
作者信息
Solomon Sharon D, Chew Emily, Duh Elia J, Sobrin Lucia, Sun Jennifer K, VanderBeek Brian L, Wykoff Charles C, Gardner Thomas W
机构信息
Wilmer Eye Institute, Johns Hopkins Medicine, Baltimore, MD.
National Eye Institute, National Institutes of Health, Bethesda, MD.
出版信息
Diabetes Care. 2017 Mar;40(3):412-418. doi: 10.2337/dc16-2641.
Abstract
摘要
相似文献
1
Diabetic Retinopathy: A Position Statement by the American Diabetes Association.糖尿病视网膜病变：美国糖尿病协会的立场声明。
Diabetes Care. 2017 Mar;40(3):412-418. doi: 10.2337/dc16-2641.
2
Erratum. Diabetic Retinopathy: A Position Statement by the American Diabetes Association. Diabetes Care 2017;40:412-418.勘误。糖尿病视网膜病变：美国糖尿病协会的立场声明。《糖尿病护理》2017年；40：412 - 418。
Diabetes Care. 2017 Jun;40(6):809. doi: 10.2337/dc17-er06e. Epub 2017 Apr 21.
3
Erratum. Diabetic Retinopathy: A Position Statement by the American Diabetes Association. Diabetes Care 2017;40:412-418.勘误。糖尿病视网膜病变：美国糖尿病协会的立场声明。《糖尿病护理》2017年；40:412 - 418。
Diabetes Care. 2017 Sep;40(9):1285. doi: 10.2337/dc17-er09. Epub 2017 Jul 13.
4
Diabetic retinopathy.糖尿病性视网膜病变
Med Clin North Am. 1978 Jul;62(4):767-85.
5
Proliferative retinopathy in patients with type 1 diabetes of less than 5 years' duration.病程小于5年的1型糖尿病患者的增殖性视网膜病变。
Diabetes Metab. 2002 Apr;28(2):141-4.
6
Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA Diabetes Trials: a position statement of the American Diabetes Association and a Scientific Statement of the American College of Cardiology Foundation and the American Heart Association.强化血糖控制与心血管事件预防：ACCORD、ADVANCE及退伍军人事务部糖尿病试验的启示：美国糖尿病协会立场声明以及美国心脏病学会基金会和美国心脏协会科学声明
J Am Coll Cardiol. 2009 Jan 20;53(3):298-304. doi: 10.1016/j.jacc.2008.10.008.
7
Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association.强化血糖控制与心血管事件预防：ACCORD、ADVANCE及退伍军人事务部糖尿病试验的启示：美国糖尿病协会立场声明及美国心脏病学会基金会和美国心脏协会科学声明
Circulation. 2009 Jan 20;119(2):351-7. doi: 10.1161/CIRCULATIONAHA.108.191305. Epub 2008 Dec 17.
8
Prevalence of diabetic retinopathy in patients with recently diagnosed diabetes mellitus.近期诊断为糖尿病患者的糖尿病视网膜病变患病率
Clin Exp Optom. 2011 Jul;94(4):371-5. doi: 10.1111/j.1444-0938.2010.00574.x. Epub 2011 Feb 16.
9
The Association of Metabolic Syndrome with Diabetic Retinopathy: The Korean National Health and Nutrition Examination Survey 2008-2012.代谢综合征与糖尿病视网膜病变的关联：2008 - 2012年韩国国民健康与营养检查调查
PLoS One. 2016 Jun 8;11(6):e0157006. doi: 10.1371/journal.pone.0157006. eCollection 2016.
10
Dermopathy and retinopathy in diabetes: is there an association?糖尿病中的皮肤病和视网膜病变：它们之间有关联吗？
Dermatology. 2007;214(2):133-6. doi: 10.1159/000098572.
引用本文的文献
1
Automated segmentation of retinal vessel using HarDNet fully convolutional networks.使用HarDNet全卷积网络对视网膜血管进行自动分割。
PLoS One. 2025 Sep 8;20(9):e0330641. doi: 10.1371/journal.pone.0330641. eCollection 2025.
2
SIRT1 as a potential target for age-related eye diseases: mechanisms and therapeutic strategies.SIRT1作为年龄相关性眼病的潜在靶点：作用机制与治疗策略
Hum Cell. 2025 Sep 7;38(6):155. doi: 10.1007/s13577-025-01285-w.
3
Early retinal changes in type 2 diabetes detected by texture-based OCT analysis: potential approach for subclinical diabetic retinopathy diagnosis.基于纹理的光学相干断层扫描分析检测2型糖尿病早期视网膜变化：亚临床糖尿病视网膜病变诊断的潜在方法
Eye Vis (Lond). 2025 Sep 3;12(1):36. doi: 10.1186/s40662-025-00451-3.
4
Impact of the COVID-19 pandemic on the Andalusian program for early detection of diabetic retinopathy: a population-based study.2019年冠状病毒病大流行对安达卢西亚糖尿病视网膜病变早期检测项目的影响：一项基于人群的研究。
Front Clin Diabetes Healthc. 2025 Aug 14;6:1631252. doi: 10.3389/fcdhc.2025.1631252. eCollection 2025.
5
Forecasting the diabetic retinopathy progression using generative adversarial networks.使用生成对抗网络预测糖尿病视网膜病变的进展。
Commun Med (Lond). 2025 Aug 23;5(1):368. doi: 10.1038/s43856-025-01092-2.
6
Identifying facilitators, barriers and areas of opportunity in diabetic retinopathy screening: quality improvement through qualitative methods.识别糖尿病视网膜病变筛查中的促进因素、障碍和机会领域：通过定性方法改进质量
BMJ Open Qual. 2025 Aug 18;14(3):e003310. doi: 10.1136/bmjoq-2025-003310.
7
Scavenging acrolein with 2-HDP preserves neurovascular integrity in a rat model of diabetic retinal disease.用2-羟基二氢吡啶清除丙烯醛可在糖尿病视网膜病变大鼠模型中维持神经血管完整性。
Diabetologia. 2025 Aug 15. doi: 10.1007/s00125-025-06515-2.
8
Comparison of the Usefulness of Optical Coherence Tomography Angiography and Fluorescein Angiography in the Diagnosis of Diabetic Macular Edema.光学相干断层扫描血管造影与荧光素血管造影在糖尿病性黄斑水肿诊断中的应用价值比较
Diagnostics (Basel). 2025 Jul 25;15(15):1873. doi: 10.3390/diagnostics15151873.
9
Plasma Sphingomyelins as Biomarkers for Diabetic Retinal Neurodegeneration: The Maastricht Study.血浆鞘磷脂作为糖尿病视网膜神经变性的生物标志物：马斯特里赫特研究
Ophthalmol Sci. 2025 Jun 27;5(6):100870. doi: 10.1016/j.xops.2025.100870. eCollection 2025 Nov-Dec.
10
Cohort profile of the Heidelberg study on diabetes and complications HEIST-DiC.海德堡糖尿病与并发症研究（HEIST-DiC）的队列概况
Sci Rep. 2025 Aug 12;15(1):29580. doi: 10.1038/s41598-025-15343-8.
本文引用的文献
1
Cost-effectiveness of ranibizumab in the treatment of visual impairment due to diabetic macular edema.雷珠单抗治疗糖尿病性黄斑水肿致视力损害的成本效果分析。
J Med Econ. 2016 Jul;19(7):663-71. doi: 10.3111/13696998.2016.1154566. Epub 2016 Mar 2.
2
Cost-effectiveness of Different Diabetic Retinopathy Screening Modalities.不同糖尿病视网膜病变筛查方式的成本效益
J Diabetes Sci Technol. 2015 Dec 29;10(2):301-7. doi: 10.1177/1932296815624109.
3
Panretinal Photocoagulation vs Intravitreous Ranibizumab for Proliferative Diabetic Retinopathy: A Randomized Clinical Trial.全视网膜光凝与玻璃体内注射雷珠单抗治疗增殖性糖尿病视网膜病变的随机临床试验
JAMA. 2015 Nov 24;314(20):2137-2146. doi: 10.1001/jama.2015.15217.
4
The Cost-Effectiveness of Ranibizumab for the Treatment of Diabetic Macular Edema.雷珠单抗治疗糖尿病性黄斑水肿的成本效果分析。
Ophthalmology. 2015 Jul;122(7):1416-25. doi: 10.1016/j.ophtha.2015.03.032. Epub 2015 Apr 29.
5
Intensive diabetes therapy and ocular surgery in type 1 diabetes.1型糖尿病的强化糖尿病治疗与眼科手术
N Engl J Med. 2015 Apr 30;372(18):1722-33. doi: 10.1056/NEJMoa1409463.
6
Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema.阿柏西普、贝伐单抗或雷珠单抗治疗糖尿病性黄斑水肿。
N Engl J Med. 2015 Mar 26;372(13):1193-203. doi: 10.1056/NEJMoa1414264. Epub 2015 Feb 18.
7
Blood pressure control for diabetic retinopathy.糖尿病视网膜病变的血压控制
Cochrane Database Syst Rev. 2015 Jan 31;1:CD006127. doi: 10.1002/14651858.CD006127.pub2.
8
Neural Retinal Disorganization as a Robust Marker of Visual Acuity in Current and Resolved Diabetic Macular Edema.神经视网膜紊乱作为当前及已消退的糖尿病性黄斑水肿中视力的可靠标志物。
Diabetes. 2015 Jul;64(7):2560-70. doi: 10.2337/db14-0782. Epub 2015 Jan 29.
9
Cost analysis of teleretinal screening for diabetic retinopathy in a county hospital population.县级医院人群中糖尿病视网膜病变远程视网膜筛查的成本分析
Diabetes Care. 2014 Dec;37(12):e252-3. doi: 10.2337/dc14-0929.
10
The 5-year onset and regression of diabetic retinopathy in Chinese type 2 diabetes patients.中国2型糖尿病患者糖尿病视网膜病变的5年发病与转归情况
PLoS One. 2014 Nov 17;9(11):e113359. doi: 10.1371/journal.pone.0113359. eCollection 2014.
Zotero 插件